Peripheral Blood Stem Cells, Delhi

Per year, about 18,000 people between the ages of 0 and 74 could benefit from a potentially life-saving bone marrow or umbilical cord blood transplant.

Stem cells develop in the bone marrow and can become any kind of cell the body requires — RBCs, WBCs, or platelets. During cancer treatment, a patient receives new blood cells to replace those damaged by chemoradiation, a process called engraftment once the donor cells are transferred to the recipient's bone marrow.

Autologous transplants use the patient's own stem cells; allogeneic transplants use stem cells from a sibling, relative, or parent; syngeneic transplants use stem cells from an identical twin.

Stem cell regeneration from the transplant is necessary to regenerate the affected stem cells and increase the viability of the bone marrow after conditioning or radiation therapy, reinforcing the immune system to fight remaining cancer cells.

It uses stem cells collected directly from a patient's circulating blood via apheresis, rather than from bone marrow or fat tissue.

Apheresis is a process where blood is drawn, passed through a machine that separates out specific components (in this case, stem cells), and the remaining blood is returned to the patient.

Not always, but it is often used to temporarily increase the number of stem cells circulating in the blood, making the apheresis collection more efficient.

Both are recognized sources. Peripheral blood is collected via apheresis; bone marrow is collected via needle aspiration. See our production of stem cells page for the full comparison.

It is available at Stem Cell Care India's facility in New Delhi, for select cases assessed during evaluation.

Sessions typically take a few hours, and more than one session may be needed depending on the number of cells required.

No. Like other stem cell sourcing methods, response varies by patient and condition. See our safety and guarantees page.

Yes. Peripheral blood stem cell treatment and Exosome Therapy for Retinal Detachment address different aspects of recovery, and the two are often coordinated within the same care plan for patients dealing with vision loss from a detached retina, when both are clinically appropriate.

Some do. Patients researching retinal blood-vessel damage, often diabetes-related sometimes explore Exosome Therapy for Retinopathy as a complementary option alongside peripheral blood stem cell treatment, with the combination assessed case-by-case during a free medical evaluation.

It can be. Exosome Therapy for Diabetic Neuropathy is a separate regenerative option some patients consider alongside peripheral blood stem cell treatment when managing nerve pain and numbness from diabetes, coordinated by the clinical team rather than self-directed.

They are complementary, not interchangeable. Peripheral blood stem cell treatment supports function and recovery directly, while Exosome Therapy for Muscular Dystrophy targets progressive muscle weakness at the cellular level; some patients use both as part of one care plan.

Yes. Peripheral blood stem cell treatment and Exosome Therapy for Osteoporosis address different aspects of recovery, and the two are often coordinated within the same care plan for patients dealing with low bone density and fracture risk, when both are clinically appropriate.

Some do. Patients researching tremor, rigidity, and movement symptoms sometimes explore Exosome Therapy for Parkinson’s Disease as a complementary option alongside peripheral blood stem cell treatment, with the combination assessed case-by-case during a free medical evaluation.

It can be. Exosome Therapy for Rheumatoid Arthritis is a separate regenerative option some patients consider alongside peripheral blood stem cell treatment when managing autoimmune joint inflammation, coordinated by the clinical team rather than self-directed.

They are complementary, not interchangeable. Peripheral blood stem cell treatment supports function and recovery directly, while Exosome Therapy for Sciatic Nerve Injury & Sciatica targets sciatic nerve pain radiating down the leg at the cellular level; some patients use both as part of one care plan.

Yes. Peripheral blood stem cell treatment and Exosome Therapy for Shoulder Injury address different aspects of recovery, and the two are often coordinated within the same care plan for patients dealing with rotator cuff and shoulder joint damage, when both are clinically appropriate.

Some do. Patients researching loss of motor or sensory function after cord damage sometimes explore Exosome Therapy for Spinal Cord Injury as a complementary option alongside peripheral blood stem cell treatment, with the combination assessed case-by-case during a free medical evaluation.

It can be. Exosome Therapy for Spinal Muscular Atrophy is a separate regenerative option some patients consider alongside peripheral blood stem cell treatment when managing motor-neuron loss and progressive weakness in SMA, coordinated by the clinical team rather than self-directed.

They are complementary, not interchangeable. Peripheral blood stem cell treatment supports function and recovery directly, while Exosome Therapy for Sports Injuries targets soft-tissue and joint injuries from athletic activity at the cellular level; some patients use both as part of one care plan.

Yes. Peripheral blood stem cell treatment and Exosome Therapy for Systemic Lupus address different aspects of recovery, and the two are often coordinated within the same care plan for patients dealing with autoimmune inflammation affecting multiple organs, when both are clinically appropriate.

Some do. Patients researching slow-healing or chronic wounds sometimes explore Exosome Therapy for Wound Healing as a complementary option alongside peripheral blood stem cell treatment, with the combination assessed case-by-case during a free medical evaluation.